Gilead Sciences Inc. (NASDAQ:GILD) insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at $250,829,982.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) opened at 75.24 on Monday. The stock has a market capitalization of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10. Gilead Sciences Inc. has a 1-year low of $74.92 and a 1-year high of $111.11. The stock has a 50 day moving average of $78.95 and a 200-day moving average of $85.05.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.15 earnings per share. Equities research analysts predict that Gilead Sciences Inc. will post $11.76 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.50%. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.
Several brokerages recently issued reports on GILD. Barclays PLC reissued an “overweight” rating on shares of Gilead Sciences in a report on Thursday, July 28th. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a report on Monday, October 3rd. Bank of America Corp. reissued a “neutral” rating and set a $100.00 target price on shares of Gilead Sciences in a report on Sunday, September 25th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Finally, Leerink Swann set a $112.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, September 22nd. Ten equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $104.71.
Several large investors have recently modified their holdings of GILD. Bank of Montreal Can purchased a new stake in shares of Gilead Sciences during the second quarter worth approximately $427,750,000. Capital World Investors increased its stake in shares of Gilead Sciences by 28.3% in the second quarter. Capital World Investors now owns 15,318,948 shares of the biopharmaceutical company’s stock worth $1,277,907,000 after buying an additional 3,380,000 shares during the period. Investec Asset Management LTD purchased a new stake in shares of Gilead Sciences during the first quarter worth approximately $280,342,000. Parnassus Investments CA increased its stake in shares of Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock worth $705,774,000 after buying an additional 2,640,284 shares during the period. Finally, NN Investment Partners Holdings N.V. purchased a new stake in shares of Gilead Sciences during the first quarter worth approximately $180,268,000. Institutional investors and hedge funds own 77.93% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.